MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ymthe.2024.01.035

Медицинская библиотека · Molecular therapy : the journal of the American Society of Gene Therapy · 2024

Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice.

Shin Dong Ho, Jiang Hong, Gillard Andrew G, Kim Debora, Fan Xuejun, Singh Sanjay K, Nguyen Teresa T, Sohoni Sagar S, Lopez-Rivas Andres R, Parthasarathy Akhila, Ene Chibawanye I, Gumin Joy, Lang Frederick F, Alonso Marta M, Gomez-Manzano Candelaria, Fueyo Juan

СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

Oncolytic viruses are a promising treatment for patients with high-grade gliomas, but neutralizing antibodies can limit their efficacy in patients with prior virus exposure or upon repeated virus injections. Data from a previous clinical trial using the oncolytic adenovirus Delta-24-RGD showed that generation of anti-viral neutralizing antibodies may affect the long-term survival of glioma patients. Past studies have examined the effects of neutralizing antibodies during systemic virus injections, but largely overlooked their impact during local virus injections into the brain. We found that immunoglobulins colocalized with viral proteins upon local oncolytic virotherapy of brain tumors, warranting a strategy to prevent virus neutralization and maximize oncolysis. Thus, we generated a chimeric virus, Delta-24-RGD-H43m, by replacing the capsid protein HVRs from the serotype 5-based Delta-24-RGD with those from the rare serotype 43. Delta-24-RGD-H43m evaded neutralizing anti-Ad5 antibodies and conferred a higher rate of long-term survival than Delta-24-RGD in glioma-bearing mice. Importantly, Delta-24-RGD-H43m activity was significantly more resistant to neutralizing antibodies present in sera of glioma patients treated with Delta-24-RGD during a phase 1 clinical trial. These findings provide a framework for a novel treatment of glioma patients that have developed immunity against Delta-24-RGD.

Для цитирования: Shin Dong Ho, Jiang Hong, Gillard Andrew G, Kim Debora, Fan Xuejun, Singh Sanjay K, Nguyen Teresa T, Sohoni Sagar S, Lopez-Rivas Andres R, Parthasarathy Akhila, Ene Chibawanye I, Gumin Joy, Lang Frederick F, Alonso Marta M, Gomez-Manzano Candelaria, Fueyo Juan. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice.. Molecular therapy : the journal of the American Society of Gene Therapy. 2024. DOI: 10.1016/j.ymthe.2024.01.035.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.